

Rocã-o Gallego-Durã;n

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6918189/publications.pdf>

Version: 2024-02-01

36
papers

1,275
citations

430754

18
h-index

377752

34
g-index

39
all docs

39
docs citations

39
times ranked

2145
citing authors

#	ARTICLE	IF	CITATIONS
1	Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?. <i>Gut</i> , 2022, 71, 382-390.	6.1	113
2	Long non-coding RNA H19 as a biomarker for hepatocellular carcinoma. <i>Liver International</i> , 2022, 42, 1410-1422.	1.9	14
3	Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation. <i>Scientific Reports</i> , 2022, 12, 3418.	1.6	19
4	Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD. <i>Journal of Gastroenterology</i> , 2022, 57, 357-371.	2.3	8
5	A Shortcut from Metabolic-Associated Fatty Liver Disease (MAFLD) to Hepatocellular Carcinoma (HCC): c-MYC a Promising Target for Preventative Strategies and Individualized Therapy. <i>Cancers</i> , 2022, 14, 192.	1.7	15
6	Detailed stratified GWAS analysis for severe COVID-19 in four European populations. <i>Human Molecular Genetics</i> , 2022, 31, 3945-3966.	1.4	46
7	Development and Validation of a Clinical-Genetic Risk Score to Predict Hepatic Encephalopathy in Patients With Liver Cirrhosis. <i>American Journal of Gastroenterology</i> , 2021, 116, 1238-1247.	0.2	12
8	Extra virgin olive oil improved body weight and insulin sensitivity in high fat diet-induced obese LDL ^r mice without attenuation of steatohepatitis. <i>Scientific Reports</i> , 2021, 11, 8250.	1.6	14
9	Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects. <i>Liver International</i> , 2021, 41, 2076-2086.	1.9	13
10	Management of NAFLD patients with advanced fibrosis. <i>Liver International</i> , 2021, 41, 95-104.	1.9	7
11	Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease. <i>EBioMedicine</i> , 2021, 70, 103521.	2.7	11
12	Co-expression gene network analysis reveals novel regulatory pathways involved in porto-sinusoidal vascular disease. <i>Journal of Hepatology</i> , 2021, 75, 924-934.	1.8	11
13	Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2021, 75, 786-794.	1.8	100
14	Development and Validation of Hepamet Fibrosis Scoring System—A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 216-225.e5.	2.4	104
15	Hepatitis C Virus Clearance by Direct-Acting Antiviral Agents Improves Endothelial Dysfunction and Subclinical Atherosclerosis: HPCAR Study. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00203.	1.3	21
16	Bacterial antigen translocation and age as BMI-independent contributing factors on systemic inflammation in NAFLD patients. <i>Liver International</i> , 2020, 40, 2182-2193.	1.9	14
17	Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. <i>Journal of Hepatology</i> , 2020, 73, 17-25.	1.8	59
18	Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease. <i>PLoS ONE</i> , 2020, 15, e0243590.	1.1	3

#	ARTICLE	IF	CITATIONS
19	A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF- β 1 dependent mechanisms. <i>Scientific Reports</i> , 2019, 9, 1439.	1.6	7
20	Impaired brain glymphatic flow in experimental hepatic encephalopathy. <i>Journal of Hepatology</i> , 2019, 70, 40-49.	1.8	55
21	A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3'UTR. <i>Journal of Hepatology</i> , 2019, 70, 494-500.	1.8	67
22	Metabolic characterization of two different non-alcoholic fatty liver disease pre-clinical mouse models. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 301-307.	0.1	2
23	Analysis of the burden and variability in the management of NAFLD patients in the clinical practice: unifying the required criteria. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 270-274.	0.1	2
24	Natural Extracts Abolished Lipid Accumulation in Cells Harboring non-favourable PNPLA3 genotype. <i>Annals of Hepatology</i> , 2018, 17, 242-249.	0.6	10
25	The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1260-1270.	1.9	70
26	Genetic and Epigenetic Regulation in Nonalcoholic Fatty Liver Disease (NAFLD). <i>International Journal of Molecular Sciences</i> , 2018, 19, 911.	1.8	100
27	miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2018, 69, 1335-1348.	1.8	121
28	Simvastatin and metformin inhibit cell growth in hepatitis C virus infected cells via mTOR increasing PTEN and autophagy. <i>PLoS ONE</i> , 2018, 13, e0191805.	1.1	33
29	Metformin modifies glutamine metabolism in an in vitro and in vivo model of hepatic encephalopathy. <i>Revista Espanola De Enfermedades Digestivas</i> , 2018, 110, 427-433.	0.1	3
30	An extra virgin olive oil rich diet intervention ameliorates the nonalcoholic steatohepatitis induced by a high-fat Western-type diet in mice. <i>Molecular Nutrition and Food Research</i> , 2017, 61, 1600549.	1.5	37
31	Lactulose reduces bacterial DNA translocation, which worsens neurocognitive shape in cirrhotic patients with minimal hepatic encephalopathy. <i>Liver International</i> , 2017, 37, 212-223.	1.9	28
32	Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1611-1618.	1.4	25
33	Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2016, 6, 31421.	1.6	33
34	Epigenetic mechanisms in non-alcoholic fatty liver disease: An emerging field. <i>World Journal of Hepatology</i> , 2015, 7, 2497.	0.8	38
35	Increased soluble CD36 is linked to advanced steatosis in nonalcoholic fatty liver disease. <i>European Journal of Clinical Investigation</i> , 2014, 44, 65-73.	1.7	49
36	Thalidomide with peginterferon alfa-2b and ribavirin in the treatment of non-responders genotype 1 chronic hepatitis C patients: proof of concept. <i>Revista Espanola De Enfermedades Digestivas</i> , 2011, 103, 619-625.	0.1	3